LVSP vs RVP in Patients With AV Conduction Disorders

Atrioventricular Block Clinical Trial

— LEAP  

Official title:

Permanent Left Ventricular Septal Pacing Versus Right Ventricular Pacing in Patients With Atrioventricular Conduction Disorders: a Randomized Trial: LEAP Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04595487
• Other study ID #: NL72047.068.20
• Status: Recruiting
• Phase: N/A
• Start date: May 1, 2021
• Est. completion date: May 1, 2025

Study information

• Verified date: April 2024
• Source: Maastricht University
• Contact: Justin Luermans, MD PhD
• Phone: +31433875093
• Email: justin.luermans[@]mumc.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Rationale:

Permanent cardiac pacing is the only available therapy in patients with atrioventricular (AV) conduction disorders and can be life-saving. Right ventricular pacing (RVP), the routine clinical practice for decades in these patients, is non-physiologic, leads to dyssynchronous electrical and mechanical activation of the ventricles, and may cause pacing-induced cardiomyopathy and heart failure.

Left ventricular septal pacing (LVSP) is an emerging form of physiologic pacing that can possibly overcome the adverse effects of RVP.

Study design and hypotheses:

The LEAP trial is a multi-center investigator-initiated, prospective, randomized controlled, open label, blinded endpoint evaluation (PROBE) study that compares LVSP with conventional RVP. A total of four hundred seventy patients with a class I or IIa indication for pacemaker implantation due to AV conduction disorders and an expected ventricular pacing percentage >20% will be randomized 1:1 to LVSP or RVP. The primary endpoint is a composite endpoint of all-cause mortality, hospitalization for heart failure and a more than 10% decrease in left ventricular ejection fraction (LVEF) in absolute terms leading to a LVEF below 50% at one year follow-up. LVSP is anticipated to result in improved outcomes.

Secondary objectives are to evaluate whether LVSP is cost-effective and associated with an improved quality of life (QOL) as compared to RVP. Quality of life is expected to improve with LVSP and reduced healthcare resource utilizations are expected to ensure lower costs in the LVSP group during follow-up, despite initial higher costs of the implantation.

Study design: Multi-center investigator-initiated, prospective, randomized controlled, open label, blinded endpoint evaluation (PROBE) study.

Study population: Adult patients with a bradycardia-pacing indication because of AV conduction disorders with an expected ventricular pacing percentage of ≥ 20% and a left ventricular ejection fraction (LVEF) >/= 40%. Four hundred seventy patients will be randomized 1:1 to LVSP or RVP.

Intervention: LVSP vs RVP.

Main study parameters/endpoints:

The primary endpoint is a composite of all-cause mortality, hospitalization for heart failure, and a more than 10% point decrease in left ventricular ejection fraction (LVEF) leading to an LVEF below 50%, which as a binary combined endpoint will be determined at one year follow-up.

Secondary endpoints are:

• Time to first occurrence of all cause mortality or hospitalization for heart failure.

• Time to first occurrence of all cause mortality.

• Time to first occurrence of hospitalization for heart failure.

• Time to first occurrence of atrial fibrillation (AF) de novo.

• The echocardiographic changes in LVEF at one year.

• The echocardiographic changes in diastolic (dys-)function at one year.

• The occurrence of pacemaker related complications.

• Quality of life (QOL), cost-effectiveness analyses (CEA) and budget impact analysis (BIA).

The secondary endpoints (other than echocardiographic LVEF change) will be determined at the end of the follow-up period, when the last included patient has reached one year follow-up. The individual follow-up time for patients at this time point will vary with a minimum of one year.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 470
• Est. completion date: May 1, 2025
• Est. primary completion date: May 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age > 18y

• Life expectancy with good functional status of > 1y

• Class I or IIa pacemaker indication due to AV conduction disorder

• Acquired 3rd or 2nd degree AVB

• Atrial arrhythmia with slow ventricular conduction

• Expected ventricular pacing percentage > 20%

• LVEF >/= 40%

• Signed and dated informed consent form

Exclusion Criteria:

• HF NYHA class III-IV

• Class I indication for CRT

• Class I indication for ICD

• Previous implanted CIED (except for ILR)

• Atrial arrhythmia with planned AV junction ablation

• PCI or CABG <30 days before enrollment

• Valvular heart disease with indication for valve repair or replacement

• Hypertrophic cardiomyopathy with interventricular septum thickness > 2 cm

• Renal insufficiency requiring hemodialysis

• Active infectious disease or malignancy

• Pregnancy

Related Conditions & MeSH terms

• Atrioventricular Block
• Cardiac Pacing
• Cardiomyopathies
• Conduction System Pacing
• Left Ventricular Septal Pacing
• Pacing-Induced Cardiomyopathy

Intervention

Procedure:
• Left ventricular septal pacing
In the LVSP group, instead of placing the standard RV lead, the commercially available 3830 Select Secure (Medtronic, Minneapolis, USA) lead is introduced via standard transvenous approach and positioned against the right ventricular side of the IVS by using the commercially available non-deflectable septal delivery sheath (C315, Medtronic, Minneapolis, USA) under fluoroscopic guidance. Subsequently this pacing lead is advanced/screwed through the interventricular septum until the left ventricular septum is reached. Accurate lead position at the left ventricular septum will be determined anatomically using fluoroscopy, and electrically by evaluating local electrograms and changes in paced electrocardiogram morphology. In case of unsuccessful lead positioning in the left ventricular septum, the Select Secure lead may be placed at the His bundle region (natural conduction system of the heart) or in the right ventricle according to the physician's discretion.
• Right ventricular pacing
In the RVP group, the ventricular pacing lead is positioned in the right ventricle.

Locations

Country	Name	City	State
Belgium	Ziekenhuis Oost Limburg	Genk
Belgium	University Hospital Gent	Gent
Czechia	University Hospital Kralovske Vinohrady	Praha
Italy	Policlinico Casilino	Rome
Netherlands	Noordwest Ziekenhuisgroep	Alkmaar
Netherlands	Reinier de Graaf Gasthuis	Delft
Netherlands	Catharina Ziekenhuis	Eindhoven
Netherlands	Medisch Spectrum Twente	Enschede
Netherlands	Maastricht University	Maastricht	Limburg
Netherlands	Sint Antonius Ziekenhuis	Nieuwegein
Poland	University Hospital Jaegellonian	Kraków
Spain	Hospital Universitario y Politecnico La Fe	Valencia
Switzerland	University Hospital of Geneva	Geneva

Sponsors (3)

Lead Sponsor	Collaborator
Maastricht University	Medtronic, ZonMw: The Netherlands Organisation for Health Research and Development

Countries where clinical trial is conducted

Belgium,  Czechia,  Italy,  Netherlands,  Poland,  Spain,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Binary combined endpoint consisting of all-cause mortality, hospitalization for heart failure, and a more than 10% point decrease in left ventricular ejection fraction (LVEF) leading to a LVEF below 50%.	Hospitalization for heart failure is defined as: hospitalization or unplanned hospital visits for heart failure requiring intravenous diuretics and/or (adjustment of) other medical heart failure therapy; hospitalization for upgrade to cardiac resynchronization therapy (CRT, ie biventricular pacing) for progression of heart failure with worsening NYHA class and/or (increased) need for diuretic therapy or other medical heart failure therapy; or hospitalization for upgrade to CRT for developing a class I indication for CRT (includes symptomatic heart failure); or hospitalization or unplanned hospital visit for heart failure triggered by an episode of atrial fibrillation with uncontrolled heart rate requiring intravenous diuretics or adjustment of rate control therapy.; All-cause mortality is defined as death from any cause and subdivided into cardiovascular and non-cardiovascular death.	Determined at one year follow-up
Secondary	Time to first occurrence of hospitalization for heart failure.	Hospitalization for heart failure is defined as: hospitalization or unplanned hospital visits for heart failure requiring intravenous diuretics and/or (adjustment of) other medical heart failure therapy; hospitalization for upgrade to cardiac resynchronization therapy (CRT, ie biventricular pacing) for progression of heart failure with worsening NYHA class and/or (increased) need for diuretic therapy or other medical heart failure therapy; or hospitalization for upgrade to CRT for developing a class I indication for CRT (includes symptomatic heart failure); or hospitalization or unplanned hospital visit for heart failure triggered by an episode of atrial fibrillation with uncontrolled heart rate requiring intravenous diuretics or adjustment of rate control therapy.	Determined at the end of the follow-up period (when the last-included patient reached the one year follow-up period)
Secondary	Time to first occurrence of all cause mortality.	All-cause mortality is defined as death from any cause and subdivided into cardiovascular and non-cardiovascular death.	Determined at the end of the follow-up period (when the last-included patient reached the one year follow-up period)
Secondary	Time to first occurrence of all cause mortality or hospitalization for heart failure.	All cause mortality and hospitalization for heart failure are defined as mentioned in secondary outcome 1 and 2.	Determined at the end of the follow-up period (when the last-included patient reached the one year follow-up period)
Secondary	Time to first occurrence of atrial fibrillation (AF) de novo.	Occurrence of atrial fibrillation de novo is defined as: Occurrence of a first clinical or subclinical episode of AF as diagnosed respectively by ECG (clinical AF) or by pacemaker interrogation (subclinical AF/atrial high rate episode, lasting > 24 hours) in patients without a history of AF.	Determined at the end of the follow-up period (when the last-included patient reached the one year follow-up period)
Secondary	The echocardiographic changes in left ventricular ejection fraction (LVEF) at one year.	Change in LVEF is based on echocardiography at one year follow-up as compared to baseline echocardiography.	Determined at one year follow-up
Secondary	The echocardiographic changes in diastolic (dys-)function at one year.	Diastolic function will be assessed by determining the following echocardiographic parameters at baseline and one year follow-up: E-wave, A-wave, E/A ratio, e' septal and lateral, E/e', 2D-strain of the left ventricle and atrium, pressure gradient across the tricuspid valve (dPTI) and volume of the left-atrium (LAVI). Diastolic function will be graded according to the current guidelines.	Determined at one year follow-up
Secondary	The occurrence of pacemaker related complications.	Pacemaker (implantation) related complications occurring during pacemaker implantation or during follow-up after pacemaker implantation consisting of: pneumothorax; cardiac tamponade; pocket hematoma requiring re-intervention; pacemaker infection; lead luxation, dislocation, or perforation requiring re-intervention; pacemaker and lead dysfunction during follow-up (elevated threshold/sensing issues/early battery depletion) requiring re-intervention.	Determined at the end of the follow-up period (when the last-included patient reached the one year follow-up period)
Secondary	Quality of Life analysis reported as Quality Adjusted Life Years (QALYs)	Quality of life will be analyzed using the EQ-5D-5L questionnaire at baseline, 6 and 12 months follow-up and every 6 months thereafter.	Determined at the end of the follow-up period (when the last-included patient reached the one year follow-up period)
Secondary	Cost effectiveness analysis (CEA)	A trial based economical evaluation from a societal perspective will be performed in accordance with the Dutch guidelines for economical evaluations in healthcare.; Resource use will be measured from a societal perspective using data from case record forms and the Medical Consumption (MCQ) and Productivity loss (PCQ) questionnaires.	Determined at the end of the follow-up period (when the last-included patient reached the one year follow-up period)
Secondary	Budget Impact Analysis (BIA)	Budget impact analysis will be performed from a societal, health care provider and health care insurer perspective. The eligible population will be estimated based on national health care data.; Costs of the intervention and heart failure costs will be included. Indirect costs will not be included. The time horizon will be 3 years. The expected uptake rate will be estimated based on a panel of experts (cardiologists, implementation specialist, patient representatives) and analyses will be performed for this expected uptake rate and several slightly higher and lower uptake rates. Uncertainties and scenarios will be discussed in a panel of experts as well and different scenarios will be analysed. Recommendations of the ISPOR task force are followed for all BIA calculations.	Determined at the end of the follow-up period (when the last-included patient reached the one year follow-up period)